Skip to content

Bleeding risk factors for inpatients with liver failure treated with artificial liver support system

Bleeding risk factors for inpatients with liver failure treated with artificial liver support system

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077144
Enrollment
Unknown
Registered
2023-10-31
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe liver disease

Interventions

Case series:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with liver failure who met the inclusion criteria were screened in the established and continuously maintained clinical database of artificial liver therapy [Ethics Approval No.2019 (668)], and patients with hepatitis B-related ACLF (HBV-ACLF) were included in this study. The diagnosis of HBV-ACLF was in accordance with the diagnostic criteria of ACLF of China Severe Hepatitis Group (COSSH) . (1) Age = 14 years old, male or female; (2) History of chronic hepatitis B virus infection; (3) Total bilirubin = 12 mg/dL (205 umol/L) and PT-INR = 1.5; (4) The treatment model of artificial liver therapy was PA followed by PE; (5) Patients agreed to be included in the clinical database of artificial liver therapy [Ethics Approval No.2019 (668)].

Exclusion criteria

Exclusion criteria: (1) Combined with hematological malignant diseases, such as hematological tumor and bone marrow suppression; use of drugs with definite bone marrow suppression or promoting bone marrow hematopoiesis; (2) Congenital or acquired abnormalities of coagulation factors and fibrinogen causing PLT reduction; (3) Disseminated intravascular coagulation; (4) Use of heparin drugs within 7 days before artificial liver treatment; (5) Use of anti-PLT drugs within 7 days before artificial liver treatment; (6) Infusion of PLT within 7 days before ALSS; (7) Bleeding within 7 days before artificial liver treatment; (8) Previous splenectomy; (9) After transplantation of liver and other organs; (10) Pregnant women.

Design outcomes

Primary

MeasureTime frame
Occurrence of a bleeding event; Changes in platelet count;

Secondary

MeasureTime frame
Demographic characteristics;Disease characteristics;

Countries

China

Contacts

Public ContactYuanji Ma

Center of Infectious Diseases, West China Hospital of Sichuan Universit

maxe.doc@163.com+86 189 8060 6465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026